Kyowa Kirin CoKYKOF 82 Receivables Turnover is 0.86 as of Dec. 2025. GuruFocus rates KYKOF with a GF Score™ of 82/100 and a GF Value™ of $17.76 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 947 Drug Manufacturers companies, Kyowa Kirin Co ranks worse than 76.45% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Kyowa Kirin Co's Revenue for the
three
months ended in Dec. 2025 was $945 Mil. Kyowa Kirin Co's average Accounts Receivable for the
three
months ended in Dec. 2025 was $1,095 Mil.
Hence, Kyowa Kirin Co's Receivables Turnover for the
three
months ended in Dec. 2025 was 0.86.
Kyowa Kirin Co (OTCPK:KYKOF) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Kyowa Kirin Co Receivables Turnover Related Terms
Kyowa Kirin Co Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Kyowa Kirin Co's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KYKOF vs ZTS, UTHR: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Kyowa Kirin Co's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kyowa Kirin Co Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kyowa Kirin Co's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Kyowa Kirin Co's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kyowa Kirin Co (KYKOF) has a Receivables Turnover of 0.86 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Kyowa Kirin Co and its competitors. According to the industry distribution chart, Kyowa Kirin Co ranks #724 out of 947 companies in the Drug Manufacturers industry, placing it in the top 76.5%.
Is Kyowa Kirin Co's Receivables Turnover too high?
Kyowa Kirin Co's current Receivables Turnover is 0.86. The Drug Manufacturers industry median Receivables Turnover is 5.07. Kyowa Kirin Co's value of 0.86 is 83% below this industry median. Based on the distribution chart, Kyowa Kirin Co ranks #724 out of 947 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Kyowa Kirin Co has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kyowa Kirin Co's Receivables Turnover compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Kyowa Kirin Co ranks #724 out of 947 companies for Receivables Turnover. This places Kyowa Kirin Co in the lower half of its industry. The industry median Receivables Turnover is 5.07. Kyowa Kirin Co's value of 0.86 is 83% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 947 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kyowa Kirin Co's current Receivables Turnover of 0.86 is 83% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Kyowa Kirin Co and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kyowa Kirin Co's current Receivables Turnover is 0.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyowa Kirin Co stock overvalued right now?
Based on GuruFocus' analysis, Kyowa Kirin Co (KYKOF) is currently considered Modestly Undervalued. The stock's GF Value™ is $17.76, compared to a current price of $14.43 — trading 18.8% below its estimated fair value. The current Receivables Turnover is 0.86 and 83% below the Drug Manufacturers industry median of 5.07. Kyowa Kirin Co's overall GF Score™ is 82/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Kyowa Kirin Co (KYKOF), the current Receivables Turnover is 0.86 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kyowa Kirin Co (KYKOF) Overvalued in 2026?
Based on GuruFocus' analysis, Kyowa Kirin Co stock appears to be undervalued.
The current stock price of $14.43 is trading 18.8% below its estimated GF Value™ of $17.76.
GuruFocus considers Kyowa Kirin Co to be Modestly Undervalued.
Key valuation signals for KYKOF:
Receivables Turnover: 0.86
GF Value™: $17.76 vs. price of $14.43 (18.8% below fair value)
Industry Position: 83% below the Drug Manufacturers median (#724 of 947)
No single metric tells the full story. See the KYKOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kyowa Kirin Co Ltd is engaged in research, development, manufacturing, sales, import and export of prescription pharmaceuticals. Its products include KHK4083/AMG 451, rocatinlimab; ziftomenib; OTL-203 KK8398, infigratinib; KHK4951, tivozanib; OTL-201; KK4277; KK2260; KK2269; KK2845; and KK8123.
82GF Score
Get the complete analysis for KYKOF
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KYKOF has been successfully added to your 
